Regeneron stock tumbles 12% after fianlimab phase‑3 failure in melanoma

Regeneron Pharmaceuticals shares plunged roughly 12% in premarket trading after the company announced that its phase‑3 trial of fianlimab, combined with cemiplimab, did not meet the study’s primary endpoint, prompting investor concern.

According to Regeneron’s May 15, 2026 update, the randomized trial compared the fianlimab/cemiplimab combo against pembrolizumab monotherapy in first‑line unresectable or metastatic melanoma and failed to show a statistically significant improvement in progression‑free survival (PFS). The company said it will reassess the program and review the data to determine next steps, including any implications for ongoing and planned studies.

The market reaction was swift: premarket price action showed a double‑digit decline, reflecting headline‑driven risk aversion among equity investors and re‑rating of clinical‑stage assets. Reports indicate the slide erased billions from Regeneron’s market capitalization as traders adjusted near‑term expectations for the firm’s oncology pipeline contribution.

In the broader context, Regeneron had recently reported solid first‑quarter results but faced pressures on some product revenues and margin items, factors that may amplify the impact of a pipeline setback. The fianlimab result is a notable setback for the company’s LAG‑3 program and could affect partner strategies and longer‑term revenue scenarios if not mitigated by additional data or alternate indications. The episode underscores how clinical outcomes remain a key catalyst for biotech valuations.

Analysts say the near‑term focus will be on detailed datasets, subgroup analyses, and management commentary to clarify whether the program can be salvaged or redeployed. Depending on what Regeneron discloses, the stock could stabilize if supportive signals emerge, or face further downside if the failure reflects fundamental limitations of the approach. Investors will watch for forthcoming updates and any strategic responses from management.